Abstract

The present invention is for treating diseases related to a1G subunit of various T-type calcium channels and, more specifically, provides an antisense oligonucleotide targeting SEQ ID NO: 1 for suppressing the expression of a gene encoding Cav3.1, and uses thereof for the treatment of various neuropsychiatric disorders including Parkinson's disease, epilepsy, essential tremor, depression, anxiety disorders, and unconsciousness.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure relates to a composition for developing hair color comprising polyphenol, a method of developing hair color using the composition, a shampoo for developing hair color comprising the composition, and a method of developing hair color using the composition. According to the present disclosure, the composition for developing hair color comprising trihydroxybenzene produces the development of hair color in brown, dark brown, or black and has excellent color development enhancing power, color development lasting power, and anti-gray hair, without using amine compounds, irritating alkaline agents, and oxidizing agents.

IPC Classes  ?

• A61K 8/34 - Alcohols
• A61Q 5/02 - Preparations for cleaning the hair
• A61Q 5/06 - Preparations for styling the hair, e.g. by temporary shaping or colouring

Abstract

The present invention relates to a Tie2 agonistic antibody that binds to an Ig3 Fn3 domain of human Tie2 or an antigen-binding fragment thereof, wherein by binding of the antibody, homodimer Tie2 can form a polygonal assembly so as to be clustered and activated.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A solid oxide fuel cell according to this invention can provide a solid oxide fuel cell with improved performance, by loading an alkali-based promoter in an anode.

IPC Classes  ?

• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides
• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture

Abstract

A complex in which a protein or a nucleic acid is coupled to a liposome produced as a pulmonary surfactant can not only be selectively delivered to the lungs without any damage to the structure of the protein or the nucleic acid and with the original form and function thereof preserved during in vivo administration, but can also efficiently deliver the coupled protein or nucleic acid (gene) to surrounding cells by being effectively fused with a pulmonary surfactant membrane present in an alveolus, and has the benefit of having little toxicity and excellent structural stability.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are: a fuel cell catalyst of which only a portion, which has relatively low catalytic activity and in which the greatest amount of platinum elution occurs and platinum oxide is easily formed, is selectively coated with a protective layer, and thus degradation due to the long-term operation of a fuel cell can be effectively prevented while also minimizing a deterioration in catalytic activity; a manufacturing method therefor; and a membrane-electrode assembly including same. The fuel cell catalyst of the present invention comprises: a nanoparticle containing platinum; and a protective layer which is selectively coated on only a portion of the surface of the nanoparticle and can suppress the oxidation of the platinum through electronic interaction with the nanoparticle.

IPC Classes  ?

• H01M 4/92 - Metals of platinum group
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 4/88 - Processes of manufacture

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating Fabry disease, containing a TSP1 protein inhibitor as an active ingredient. Particularly, in vascular endothelial cells produced by knocking out a TSP1 gene in induced pluripotent stem cells derived from a Fabry disease patient, of the present invention, the recovery of cell morphology, a decrease in the expression of a TSP1 gene, a decrease in the expression levels of a TSP1 protein and a phosphorylated-SMAD protein, which are anti-angiogenic factors, and an increase in the expression levels of a KDR protein and an eNOS protein, which are angiogenic factors, have been confirmed, and thus a TSP1 gene expression inhibitor or a TSP1 protein activity inhibitor can be effectively used in the treatment of Fabry disease.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A23L 33/13 - Nucleic acids or derivatives thereof
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to an antibody against Tie-2 or an antigen binding fragment thereof, a nucleic acid for coding same, a vector comprising said nucleic acid, a cell transformed with said vector, a method for producing said antibody or the antigen binding fragment thereof, and a composition for preventing or treating angiogenic diseases, comprising said antibody or the antigen binding fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Methods and apparatus for enhanced visualization of anomalies in a structure. The method comprises: acquiring pulse~echo laser ultrasonic wave propagation imaging video data at a multiplicity of points in a scan area on a surface of a structure; post-processing the pulse~echo laser ultrasonic wave propagation imaging video data using multiple-time window amplitude mapping to create a multiple-time window amplitude map; and displaying the multiple-time window amplitude map on a graphical user interface.

IPC Classes  ?

• G01N 29/14 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object using acoustic emission techniques

Abstract

The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention provides an angiogenesis inhibitor and a composition for prevention and treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present invention relates to a method for producing a lactam compound from dioxazolone in the presence of a catalyst having a particular ligand, and to a lactam compound produced thereby, and can produce a lactam compound with excellent selectivity and an excellent yield by using the combination of a starting material having a particular functional group and a particular catalyst having a particular ligand.

IPC Classes  ?

• C07D 209/34 - Oxygen atoms in position 2
• C07D 201/02 - Preparation of lactams
• C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
• C07D 209/54 - Spiro-condensed
• C07D 209/96 - Spiro-condensed ring systems
• C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• C07D 221/10 - Aza-phenanthrenes
• C07D 273/08 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups having two nitrogen atoms and more than one oxygen atom
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System

Abstract

The present invention relates to a novel metal complex, a method for producing same, and a method for producing a gamma-lactam compound using same, and the metal complex according to the present invention is used as a catalyst for producing a gamma-lactam compound and can efficiently produce a gamma-lactam compound with an excellent yield and excellent selectivity.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
• B01J 31/22 - Organic complexes
• C07D 209/46 - Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1

Abstract

The present invention relates to a novel pharmaceutical composition for the treatment of dystonia or the relief of pain caused by muscle tension and provides a pharmaceutical composition comprising a serotonin receptor 5-HT2A inhibitor as an effective ingredient for treating dystonia or relieving pain caused by muscle tension.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/15 - Oximes (C=N—O—); Hydrazines (N—N); Hydrazones (N—N=)
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics

Abstract

The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• A61P 35/00 - Antineoplastic agents
• C07K 14/71 - Receptors; Cell surface antigens; Cell surface determinants for growth regulators
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to a CRISPR nanocomplex for nonviral genome editing, a method for preparing the same, and the like. The CRISPR nanocomplex for nonviral genome editing of the present invention has a size of several nanometers to several microns, enables intracellular delivery without external physical stimulation, and can be utilized for genome editing through nonviral routes with respect to target genes of cells. As a result, when used for preparation of animal model, microbiological engineering, cell engineering for disease treatment, or formulations for biological administration, the CRISPR Nanocomplex shows high intracellular delivery and gene editing efficiency, and can minimize problems, such as nonspecific editing, gene mutation, and induction of cytotoxicity and biotoxicity.

IPC Classes  ?

• C12N 11/02 - Enzymes or microbial cells immobilised on or in an organic carrier
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/14 - Hydrolases (3.)
• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 11/00 - Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Provided is a pressure tank having a lattice structure, including: a tank body that has a high-pressure fluid accommodated therein and is manufactured to have a prismatic shape; and cell structures that are disposed in the prismatic tank body, are manufactured in a lattice form, arrive from one side wall of the tank body to the other side wall thereof facing it, and are orthogonally arranged regularly.

IPC Classes  ?

• F17C 1/08 - Integral reinforcements, e.g. ribs
• F17C 1/02 - Pressure vessels, e.g. gas cylinder, gas tank, replaceable cartridge involving reinforcing arrangements

Abstract

The present invention relates to a mutant microorganism producing succinic acid capable of simultaneously using sucrose and glycerol as carbon sources, and more particularly, to a mutant microorganism producing succinic acid, wherein the microorganism uses both sucrose and glycerol in producing succinic acid by weakening a catabolite inhibition mechanism of the glycerol by means of sucrose. When the mutant microorganism producing succinic acid according to the present invention is cultured, succinic acid can be produced with high productivity, while maximizing conventional fermentation yield to a nearly theoretical yield and minimizing by-products.

IPC Classes  ?

• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group

Abstract

Provided are a three-dimensional (3D) sound reproducing method and apparatus. The method includes transmitting sound signals through a head related transfer filter (HRTF) corresponding to a first elevation, generating a plurality of sound signals by replicating the filtered sound signals, amplifying or attenuating each of the replicated sound signals based on a gain value corresponding to each of speakers, through which the replicated sound signals will be output, and outputting the amplified or attenuated sound signals through the corresponding speakers.

IPC Classes  ?

• H04R 5/02 - Spatial or constructional arrangements of loudspeakers
• H04S 5/02 - Pseudo-stereo systems, e.g. in which additional channel signals are derived from monophonic signals by means of phase shifting, time delay or reverberation of the pseudo four-channel type, e.g. in which rear channel signals are derived from two-channel stereo signals

Abstract

A mutant microorganism having the ability to produce putrescine and a method of preparing the microorganism in which at least one gene involved in the putrescine degradation or utilization pathway, selected from the group consisting of speE, speG, argl and puuP gene is inactivated or deleted and at least one gene selected from the group consisting of a puuA gene encoding .gamma.-glutamylputrescine synthase, a ygjG gene encoding putrescine transaminase and an argF gene encoding ornithine carbamoyltransferase chain F-monomer is further inactivated or deleted. The mutant microorganism and method providing a renewable biomass-derived source of produced putrescine as an alternative to the current chemical production processes available.

IPC Classes  ?

• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
• C12N 15/54 - Transferases (2)
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12P 13/00 - Preparation of nitrogen-containing organic compounds

Abstract

The present invention relates to a rumen bacterial mutant producing homo- succinic acid and a method for producing homo-succinic acid using the same, and more particularly to a rumen bacterial mutant producing succinic acid at a high concentration while producing little or no other organic acids in anaerobic conditions, which is obtained by disrupting a gene encoding lactate dehydrogenase (idhA), a gene encoding phosphotransacetylase (pta), and a gene encoding acetate kinase (ackA), without disrupting a gene encoding pyruvate formate lyase (p.beta.), as well as a method for producing succinic acid using the same. The inventive rumen bacterial mutant has the property of having a high growth rate and succinic acid productivity while producing little or no organic acids, as compared to the prior strains producing succinic acid. Thus, the inventive rumen bacterial mutant is useful to produce succinic acid for industrial use.

IPC Classes  ?

• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material

Abstract

Disclosed are hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for gene therapy in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be advantageously used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention relates to novel rumen bacterial mutants resulted from the disruption of a lactate dehydrogenase gene (ldhA) and a pyruvate formate- lyase gene (pfl) (which are involved in the production of lactic acid, formic acid and acetic acid) from rumen bacteria; a novel bacterial mutant (Mannheimia sp. LPK7) having disruptions of a lactate dehydrogenase gene (ldhA), a pyruvate formate-lyase gene (plf), a phosphotransacetylase gene (pta), and a acetate kinase gene (ackA); a novel bacterial mutant (Mannheimia sp. LPK4) having disruptions of a lactate dehydrogenase gene (ldhA), a pyruvate formate-lyase gene (pfl) and a phosphoenolpyruvate carboxylase gene (ppc) involved in the immobilization of CO2 in a metabolic pathway of producing succinic acid; and a method for producing succinic acid, which is characterized by the culture of the above mutants in anaerobic conditions. The inventive bacterial mutants have the property of producing succinic acid at high concentration while producing little or no organic acids, as compared to the prior wild-type strains of producing various organic acids. Thus, the inventive bacterial mutants are useful as strains for the industrial production of succinic acid.

IPC Classes  ?

• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material

Abstract

The present invention relates to a composition containing sHSPs for prevention of protein degradation and a composition for two-dimensional gel electrophoresis. Furthermore, the present invention relates to the improved method of two-dimensional gel electrophoresis, which is characterized by using sHSPs. According to the present invention, decreasing of protein spots was prevented in the two-dimensional gel electrophoresis, thereby obtaining two- dimensional gel with much more protein spots.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof